How to Get Leqvio (Inclisiran) in Pennsylvania

What Is Leqvio and Why LDL-C Control Matters

Leqvio is a small-interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA in hepatocytes, reducing LDL-receptor degradation and lowering circulating LDL-C by roughly 50% with only two injections per year after the loading phase. The FDA approved inclisiran in December 2021 for adults with HeFH or established ASCVD who need additional LDL-C lowering on top of maximally tolerated statin therapy [1].

The clinical case for aggressive LDL-C management is strong. Each 1 mmol/L (~38.7 mg/dL) reduction in LDL-C reduces major vascular events by approximately 22%, according to the Cholesterol Treatment Trialists' (CTT) meta-analysis of 26 randomized trials involving 169,138 participants [2]. For patients who cannot reach goal on statins or ezetimibe alone, PCSK9 inhibition represents one of the most effective tools available.

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD, maximize statin therapy; if LDL-C remains ≥70 mg/dL, adding ezetimibe is reasonable, and if further reduction is needed, a PCSK9 inhibitor may be considered" [3]. Inclisiran offers the same mechanistic target as monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab) but differs in its twice-yearly dosing, which may improve adherence over self-administered biweekly injections [4].

The Clinical Evidence: ORION-10 and ORION-11

In ORION-10 (N=1,561, patients with ASCVD), inclisiran 284 mg reduced LDL-C by 52.3% from baseline at day 510 versus a 0.5% increase in the placebo group (P<0.001) [5]. In the companion ORION-11 trial (N=1,617, patients with ASCVD or ASCVD risk equivalents including HeFH), LDL-C fell 49.9% with inclisiran versus a 0.8% increase with placebo at day 510 (P<0.001) [5]. Adverse event rates were comparable between active and placebo arms in both trials, with injection-site reactions being the most common drug-related event (2.6% inclisiran vs. 0.9% placebo).

The ORION-9 trial (N=482) specifically enrolled patients with HeFH and found a 39.7% placebo-corrected reduction in LDL-C at day 510 [6]. Taken together across ORION-9, ORION-10, and ORION-11, the pooled inclisiran-treated population achieved a time-averaged LDL-C reduction of approximately 50% over 18 months. The ongoing ORION-4 cardiovascular outcomes trial (N=15,000, ClinicalTrials.gov NCT03705234) is expected to report hard MACE data by 2026 [7].

Who Qualifies for Leqvio in Pennsylvania

The FDA label restricts inclisiran to two populations: adults with primary hyperlipidemia (including HeFH) and adults with established ASCVD [1]. Pennsylvania Medicaid and most commercial insurers mirror these indications but add step-therapy requirements.

Standard qualification criteria you will need to document for prior authorization include:

• A confirmed diagnosis of HeFH (genetic testing, Dutch Lipid Clinic Network score ≥6, or FH clinical criteria) or established ASCVD (prior MI, stroke, peripheral arterial disease, or coronary revascularization)
• Current or recent use of maximally tolerated statin therapy (typically high-intensity atorvastatin 40-80 mg or rosuvastatin 20-40 mg)
• LDL-C remaining above goal (≥70 mg/dL for very-high-risk ASCVD, ≥100 mg/dL for high-risk HeFH) despite statin plus ezetimibe
• Documentation of statin intolerance if statins were not completed

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies states: "For patients with very high-risk ASCVD and LDL-C ≥70 mg/dL despite maximally tolerated statin and ezetimibe, PCSK9 inhibitor therapy is recommended" [8]. This language directly supports prior authorization appeals when an insurer initially denies coverage.

Finding a Prescriber in Pennsylvania

Any Pennsylvania-licensed MD, DO, NP (certified registered nurse practitioner), or PA (physician assistant) may prescribe inclisiran. Cardiologists and lipid specialists write the majority of Leqvio prescriptions, but primary care physicians and internists can also prescribe after reviewing a patient's lipid panel and cardiac history.

In-person options include academic cardiology practices at Penn Medicine, UPMC, Jefferson Health, and Geisinger, as well as community cardiology groups and FH specialty clinics. Pennsylvania has 22 FH Foundation-affiliated clinics listed in the national FH clinic directory [9].

Telehealth options are equally valid. Pennsylvania permits synchronous audio-video telehealth prescribing for established and new patients, provided the prescriber holds an active Pennsylvania license. The Pennsylvania State Board of Medicine confirmed in its 2023 telehealth guidance that a prescriber-patient relationship can be established via live video [10]. HealthRX connects Pennsylvania residents with board-certified physicians who routinely manage HeFH and ASCVD and can initiate inclisiran therapy without requiring an in-person visit for most patients.

Step-by-Step Process: From First Visit to First Injection

Step 1. Schedule a lipid or cardiology consultation (in-person or telehealth). Bring your most recent lipid panel (dated within 90 days), current medication list, and any records documenting statin use or intolerance. A telehealth visit typically lasts 20 to 30 minutes.

Step 2. Get baseline labs. Your prescriber will order or review an LDL-C, hepatic function panel (ALT, AST), and a comprehensive metabolic panel. Some prescribers also request a fasting lipid panel, Lp(a), and an apolipoprotein B level to characterize cardiovascular risk more precisely [3].

Step 3. Prior authorization submission. The prescriber's office submits the PA request to your insurer with clinical notes, lab values, and documentation of prior statin and ezetimibe therapy. Pennsylvania commercial plans (Highmark, Independence Blue Cross, Aetna PA, Cigna PA, UPMC Health Plan) each have their own forms, but most require the same core data set. Pennsylvania Medicaid (MA fee-for-service and managed care organizations including Keystone First, UPMC for Life, and Geisinger Health Plan) covers inclisiran with prior authorization under the HeFH and ASCVD indications.

Step 4. PA determination. Most insurers respond within 3 to 14 business days. If denied, a peer-to-peer review between your prescriber and the insurer's medical director resolves approximately 40 to 60% of first-level denials, based on published prior-authorization appeal data across specialty drugs [11].

Step 5. Specialty pharmacy dispensing. Once approved, the prescription is routed to a specialty pharmacy in the Novartis distribution network. Walgreens Specialty, CVS Specialty, and Accredo are active in Pennsylvania. The pharmacy ships the drug in temperature-controlled packaging directly to the prescribing clinic or to a patient's home if home administration is arranged.

Step 6. First injection. The 284 mg dose is administered subcutaneously (abdomen, upper arm, or thigh) at day 1 by a licensed clinician. A second dose follows at month 3, then every 6 months thereafter. Clinic staff or a home-visit nurse can administer subsequent doses; some practices allow trained patients to self-inject after a demonstrated technique visit.

Total timeline: two to six weeks from first appointment to first injection, depending on insurer response time.

Labs Required Before Starting Leqvio in Pennsylvania

A prescriber reviewing your chart for inclisiran eligibility will typically want the following laboratory work dated within 60 to 90 days:

| Lab | Why It Is Needed | Target / Flag Value | |-----|-----------------|-------------------| | Fasting LDL-C | Establishes baseline and confirms need for therapy | Above goal despite statin/ezetimibe | | Non-HDL-C and apolipoprotein B | Secondary markers of residual risk | ApoB <70 mg/dL is often the secondary target | | ALT and AST | Hepatic safety screen before starting siRNA therapy | <3x upper limit of normal | | Comprehensive metabolic panel | Renal function, glucose, electrolytes | No specific contraindication threshold | | TSH | Thyroid dysfunction can cause secondary dyslipidemia | Within reference range or treated | | Lp(a) | Elevated Lp(a) is a common co-contributor in FH patients | Identify if >50 mg/dL for additional risk |

The FDA prescribing information for inclisiran does not specify mandatory monitoring labs during treatment, but the 2022 ACC/AHA lipid guideline recommends repeating a fasting lipid panel at 4 to 12 weeks after initiation to confirm response [3]. A 50% or greater LDL-C reduction from baseline is the expected pharmacodynamic response and serves as confirmation of adherence and drug effect.

Prior Authorization Documentation Checklist for Pennsylvania Insurers

Pennsylvania insurer PA requirements for inclisiran are among the more standardized in the mid-Atlantic region, but the documentation package still requires careful assembly. Your prescriber's office should prepare:

1. Completed insurer-specific PA form (available on each plan's provider portal)
2. Current lipid panel showing LDL-C above goal
3. Documentation of at least 90 days of high-intensity statin therapy or a letter documenting statin intolerance with supporting clinical notes
4. Documentation of ezetimibe use (or contraindication) at 10 mg daily
5. Confirmed diagnosis code: ICD-10 E78.01 (pure hypercholesterolemia, familial) or applicable ASCVD code (I25.10, I63.x, I73.9, etc.)
6. Prescriber's DEA number and Pennsylvania medical license number
7. NPI and pharmacy benefit routing information

If the initial PA is denied, Pennsylvania law (Act 68 of 1998, the Managed Care Consumer Protection Act) gives patients and providers the right to an expedited external appeal within 24 to 72 hours for urgent cases and a standard external appeal within 45 days [12]. Use the 2022 ACC Expert Consensus statement cited above as supporting literature in the appeal letter.

Telehealth Prescribing for Leqvio in Pennsylvania: What to Expect

Pennsylvania implemented permanent telehealth prescribing authority for controlled and non-controlled substances in Act 2023-26 [10]. Inclisiran is not a controlled substance, so there are no DEA-specific restrictions on telehealth prescribing. A prescriber needs only an active Pennsylvania license and a synchronous audio-video visit to initiate therapy.

During a telehealth consultation, the clinician will review your uploaded lab results, medication history, and cardiovascular risk profile. Most HealthRX telehealth visits for lipid management run 20 to 30 minutes. The prescriber can submit the PA request electronically the same day. If your labs are recent and your prior medication history is well-documented, the entire pre-injection process may require only a single telehealth appointment.

One practical note: the injection itself must be administered by a licensed clinical professional at a clinic, infusion center, or via a home-visit nursing service. Telehealth handles the prescription and PA; the physical injection still requires a hands-on clinical setting unless home self-injection has been arranged and trained.

Cost, Copay Assistance, and Novartis Support Programs

The wholesale acquisition cost of inclisiran is approximately $3,250 per dose (two doses per year after the loading phase equals roughly $6,500 per year before rebates). Most commercially insured patients pay substantially less after insurer negotiation and manufacturer copay assistance.

Novartis operates the Leqvio Copay Program, which may reduce out-of-pocket costs to as low as $0 per dose for eligible commercially insured patients. Patients can enroll at the Novartis patient support portal. Pennsylvania Medicaid beneficiaries covered under fee-for-service MA or a managed care organization do not use the commercial copay program but are covered under the Medicaid benefit with no additional copay once prior authorization is approved.

For uninsured or underinsured Pennsylvania residents, the Novartis Patient Assistance Program (Novartis Care) provides inclisiran at no cost to eligible patients who meet income criteria (generally household income at or below 400% of the federal poverty level) [13]. Applications are submitted through the prescriber's office.

503A Compounding Pharmacies and Inclisiran in Pennsylvania

Inclisiran (Leqvio) is an FDA-approved biologic siRNA. Pennsylvania-licensed 503A compounding pharmacies may compound medications for individual patients when a commercial product is unavailable, but FDA guidance limits compounding of FDA-approved drugs to narrow circumstances (e.g., documented allergy to an excipient that cannot be accommodated by the commercial product) [14].

For the vast majority of Pennsylvania patients, the appropriate pathway is the FDA-approved Leqvio through specialty pharmacy, not a compounded preparation. Any compounded inclisiran product would lack the ORION trial safety and efficacy data, and no compounded siRNA product currently has peer-reviewed clinical evidence supporting its use. Patients and prescribers should request the branded, FDA-approved product through the standard specialty pharmacy channel.

Transferring an Existing Leqvio Prescription to Pennsylvania

If you are moving to Pennsylvania or switching to a Pennsylvania-based telehealth provider, transferring your inclisiran prescription is straightforward. Inclisiran is dispensed through specialty pharmacies with national networks, so Walgreens Specialty, CVS Specialty, and Accredo can continue filling your prescription once a Pennsylvania-licensed prescriber takes over your care.

The new prescriber will need to review your injection history, confirm your current LDL-C response (typically a 50% or greater reduction from baseline), and submit a new PA request to your Pennsylvania insurer if you have changed plans. Bring documentation of your prior doses (dates, lot numbers if available), your most recent lipid panel, and a clinical summary from your previous provider.

Pennsylvania does not impose a waiting period or mandatory new-patient workup before a prescriber can assume management of an ongoing inclisiran regimen, provided the prescriber reviews the chart and documents medical necessity.

Monitoring After Starting Inclisiran

After the first injection, your prescriber will recheck a fasting lipid panel at 4 to 12 weeks to verify LDL-C response. The expected reduction is 50% or more from baseline. If the reduction is less than 30%, the prescriber should assess adherence to concomitant statin therapy and consider whether secondary causes of hyperlipidemia (hypothyroidism, nephrotic syndrome, obstructive liver disease) are present [3].

No routine safety labs are mandated by the FDA label during maintenance therapy, but many lipidologists check hepatic function at 3 to 6 months during the first year as a precaution, given the hepatic mechanism of action [5]. Injection-site reactions are generally mild and self-limited. Patients should report any persistent redness, swelling, or induration at the injection site to their prescriber.

The every-6-month dosing schedule means most patients need only two clinic or home-visit appointments per year for injections, plus a telehealth or in-person check-in to review labs. This schedule is substantially less burdensome than the biweekly self-injection regimens required with evolocumab (Repatha) or alirocumab (Praluent).